With Revlimid sales down, BMS slashes 2023 revenue projection
Jul 27, 2023 · BMS sliced its 2023 sales projection for blood cancer drug Revlimid by a whopping $1 billion and cut its overall revenue projection. Instead of a previous forecast of a 2% revenue …
Bristol Myers Squibb's Revlimid finally faces competition in the …
Mar 7, 2022 · Sales of Bristol Myers Squibb’s Revlimid crescendoed at $12.8 billion in 2021, the final year of exclusivity for the multiple myeloma treatment. But now, BMS can no longer hold …
Focus on new products at pharma companies as generic Revlimid ...
1 day ago · The NSE Pharma index outperformed the benchmark Nifty 50 index by a wide margin in 2024 as drug companies benefited from a benign pricing environment in the US and …
BMS reports 2% revenue loss in 2023 after Revlimid generics hurt …
Feb 2, 2024 · The company saw a decrease in sales of Revlimid (lenalidomide) following the entry of generic versions after its patent loss in 2022. Revlimid generated $6bn in 2023, compared …
BMS feels the pain of Revlimid erosion, cutting forecasts
Jul 28, 2023 · The hardest hit in its second-quarter results update was to blood cancer therapy Revlimid (lenalidomide), which is now expected to make around $5.5 billion this year – fully $1 …
Dr Reddy's surges 4% on Nuvama upgrade to 'buy ... - Moneycontrol
2 days ago · Nuvama expect Dr Reddy's new launches--Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026. …
Amid generic attack, BMS's Revlimid shows it can take a punch
Jul 27, 2022 · For now, BMS is sticking with its guidance for 2022 Revlimid sales to fall between $9 and $9.5 billion. Sales of the drug crescendoed at $12.8 billion last year. In fact, Revlimid's...
Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma
3 days ago · “These FDA approvals are good news for patients with multiple myeloma, who may now benefit from these more effective initial treatments,” said Elizabeth Hill, M.D., a multiple …
What’s after Revlimid for Dr Reddy’s, Cipla, and Sun Pharma?
Feb 20, 2024 · Frontline pharmaceutical majors Cipla, Sun Pharma and Dr Reddy’s have had bumper earnings over the last few quarters, thanks to the high-margin blockbuster cancer drug …
Bristol Myers profit beats estimates on resilient Revlimid sales
Jul 27, 2022 · Bristol Myers Squibb Co on Wednesday reported bigger second-quarter profit than expected as sales of its blockbuster cancer drug Revlimid did not drop as steeply as feared …
- Some results have been removed